Alex Aliper, PhD, is the President of Insilico Medicine. He pioneered the application of AI in multi-omics data for drug discovery and drug repurposing, generative chemistry and generative biology and put an AI-designed drug into human clinical trials. Alex Aliper built a team of over 100 AI engineers that developed state-of-the-art software products for target discovery, small molecule generation and clinical trial outcome prediction. He was recognised as "Top 100 AI Leaders in Drug Discovery and Advanced Healthcare" by Deep Knowledge Analytics. In 2020 Endpoint News selected Alex Aliper as the top 20 under 40 biotechnology executives globally.